One of the reasons is that most targets identified in HCC, e.g., TERT promoter-activating mutation, TP53 loss of function, CTNNB1-activating mutation and RAS–PI3K–mTOR pathway alterations are not yet druggable [95,96]. The gene discussed is TP53; the disease is hepatocellular carcinoma.